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As a result of selective pressure exerted 
by pathogens, both innate and adap-
tive  human  immune  responses  have 
evolved to protect us from the poten-
tially  fatal  consequences  of  infectious 
diseases (Coffman et al., 2010; Sallusto 
et al., 2010). Pattern recognition recep-
tors (PRRs) sense microorganisms to 
alert the host to the invading pathogen 
(Coffman et al., 2010) and induce im-
mediate nonspecific immune responses 
that can partially curtail the growth and 
dissemination of the microbe. More im-
portantly,  these  innate  responses  also 
shape the magnitude, quality, and dura-
bility  of  adaptive  immune  responses 
(Pulendran and Ahmed, 2006). It is the 
adaptive T and B cell response that elim-
inates the infection and confers long-
term protective immunity against the 
same pathogen. The durability of pro-
tective immunity after an acute infec-
tion can be quite remarkable and, in 
some instances, can last for a lifetime 
(Ahmed and Gray, 1996). It was this 
observation  that  led  to  the  use  of   
attenuated live microbes for vaccina-
tion,  which  resulted  in  the  develop-
ment of our most successful vaccines 
against diseases such as smallpox, polio, 
mumps, rubella, measles, and yellow   
fever (Plotkin et al., 2008).
The live attenuated yellow fever virus 
vaccine (YFV-17D) was developed in   
the late 1930s by Max Theiler at The 
Rockefeller Foundation by serial passage 
of a virulent YFV strain in cell cultures 
prepared  from  embryonated  chicken 
eggs  (Theiler  and  Smith,  1937).  This 
clever trick of passaging a virulent human 
virus in a different host cell in vitro to 
alter the virus properties resulted in the 
selection of a YFV strain (17D) that was 
attenuated but still retained immuno-
genicity. Within  a  few  years  of  its 
  introduction,  the  live  YFV-17D  vac-
cine dramatically reduced the incidence 
of the disease in humans, and to this day 
it remains one of the most successful vac-
cines ever developed. Max Theiler was 
awarded the 1951 Nobel Prize in Physi-
ology or Medicine for his findings on 
vaccination against yellow fever.
The YFV-17D strain replicates in 
humans to sufficient levels to induce 
potent T and B cell responses, but the 
infection is rapidly cleared with mini-
mal or no clinical symptoms. In many 
ways this live viral vaccine captures the 
right balance between attenuation and 
immunogenicity and confers protective 
immunity that can last for decades or 
longer (Monath et al., 2008). Protec-
tion against YFV is mediated primar-
ily by circulating antibody, and a single 
YFV-17D immunization can generate 
neutralizing  antibody  responses  that 
persist for up to 30 yr. This vaccine also 
induces highly polyfunctional and long-
lived CD4 and CD8 T cell responses 
(Gaucher  et  al.,  2008;  Miller  et  al., 
2008; Akondy et al., 2009). Thus, the 
YFV-17D vaccine offers an opportu-
nity to understand how an acute viral 
infection generates both humoral and 
cellular long-term immunity in humans 
and to apply this knowledge to devel-
oping new vaccines.
It is of particular interest to define 
the innate responses that are neces-
sary for generating such effective T and   
B cell immunity. This information will 
provide a framework for the rational 
development of adjuvants to enhance 
vaccine  efficacy.  Accordingly,  recent 
work  presented  detailed  longitudinal 
analysis of adaptive immune responses 
induced by the YFV-17D vaccine in 
humans,  along  with  systems  biology 
data documenting innate gene expres-
sion  signatures  associated  with  these 
adaptive responses (Gaucher et al., 2008; 
Querec et al., 2009). These studies re-
vealed that YFV-17D triggers multiple 
Toll-like receptors (TLRs), as well as 
RIG-I  and  MDA-5,  and  identified 
innate gene signatures that predict im-
munogenicity of the vaccine (Querec   
et  al.,  2006,  2009;  Gaucher  et  al., 
2008). These  systems  biological  ap-
proaches offer unprecedented oppor-
tunities to study the human immune 
response and to describe the component 
participants  (genes,  miRNAs,  proteins, 
and cells) of an immune response to a 
vaccine  or  pathogen  (Germain,  2010; 
Pulendran et al., 2010). The ultimate 
goals  of  this  approach,  as  applied  to 
vaccinology, are to delineate novel mole-
cular pathways by which vaccines me-
diate protective immune responses and 
to identify signatures that will predict 
vaccine immunogenicity and efficacy.
In  this  issue,  the  paper  from  the 
laboratories  of  Steinman  and  Sekaly 
(Caskey et al., 2011) uses a systems bi-
ology approach to ask whether an ad-
juvant can mimic the innate signature 
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Better  adjuvants  are  urgently  needed, 
both for new vaccines against challenging 
diseases like HIV, malaria, and tubercu-
losis and to increase the efficacy of ex-
isting vaccines in the elderly population 
and immune-compromised individuals.
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the expression of TNFSF13B (BAFF), 
which  binds  TNFRSF17  (BCMA),   
a  protein  which  regulates  differentia-
tion  of  antibody-producing  cells.  Im-
portantly,  TNFRSF17  is  part  of  the 
gene  signatures  that  predict  the  mag-
nitude of the antibody responses to the 
yellow  fever  vaccine  (Querec  et  al., 
2009) and the inactivated seasonal in-
fluenza vaccine (Nakaya et al., 2011).   
Poly ICLC also increased the expression 
of  genes  encoding  components  of  the   
complement pathway (C1QB, C3AR1, 
and SERPING1), as well as of EIF2AK2,   
which encodes protein kinase RNA-
activated  (PKR),  a  viral  sensor  that 
mediates the integrated stress response 
(García et al., 2006). Interestingly, the 
expression of genes encoding C1QB and 
EIF2AK4 (a homologue of EIF2AK2) 
have been shown to be predictors of the 
CD8 T cell response to the YFV-17D 
vaccine  (Querec  et  al.,  2009).  Thus, 
there appears to be a striking similarity 
in the innate signatures induced by the 
adjuvant poly ICLC and the viral vac-
cine YFV-17D.
The well designed human study by 
Caskey et al. (2011) represents an im-
portant first step in identifying adju-
vants that mimic the innate signatures 
of a successful viral vaccine. However, 
it is worth noting that viral infections 
are likely to “push many more buttons” 
given the broader range of interactions 
they have with the immune system. For 
example, YFV-17D stimulates multiple 
TLRs and is likely to target a wider 
spectrum of cell types, including several 
DC subsets that express these recep-
tors. Furthermore, previous studies have 
shown  that  distinct  but  overlapping 
signatures are induced by different TLR 
ligands (Amit et al., 2009). Therefore, 
the  complexity  of  innate  signatures   
induced  by  YFV-17D  is  likely  to  be 
much  greater  than  that  induced  by 
poly ICLC. Caskey et al. (2011) appro-
priately point out that pathways such as 
IL-1 signaling and protein ubiquitina-
tion are stimulated by YFV-17D but not 
poly ICLC. Future studies addressing 
these issues in more depth and exam-
ining gene signatures in isolated DC 
subsets will pave the way toward the ratio-
nal development of improved adjuvants. 
of the YFV-17D vaccine. The authors 
examined the innate immune response 
to the synthetic double-stranded RNA 
(poly ICLC), a ligand for TLR3 and 
MDA-5, in 12 healthy adult volunteers. 
Eight subjects were injected subcutane-
ously with 1.6 mg of clinical grade poly 
ICLC (a dose used previously in phase I 
trials). The remaining four subjects rep-
resented the placebo group and received 
sterile saline. After poly ICLC adminis-
tration, subjects developed erythema and 
induration at the site of injection and 
showed  mild  transient  flu-like  symp-
toms, but no serious adverse events were   
reported and there were no significant 
changes in total blood cell counts or se-
rum chemistry. Thus, in this small co-
hort,  poly  ICLC  appeared  to  be  safe 
with tolerable side effects. They next 
assessed  the  molecular  signatures  in-
duced by poly ICLC using transcrip-
tional profiling. Whole blood samples 
were collected just before poly ICLC or 
placebo administration and at multiple 
time points thereafter (6 and 12 h and   
1, 2, 3, 7, 14, and 28 d). Bioinformatics 
analysis revealed similar gene expression 
responses to poly ICLC among the vol-
unteers, with a peak response at day 1 
for five out of eight individuals and at 
12 h for the remaining three. In all sub-
jects, responses returned to baseline by 
day 7. More than 200 genes were differ-
entially expressed in the adjuvant group 
relative to the placebo group. Notably, 
there was no differential expression of 
genes induced in the placebo group. 
Poly ICLC induced expression of genes 
encoding TLR7 and TLR4, the RIG-I 
and MDA-5 viral sensors, and transcrip-
tion factors involved in type I IFN re-
sponses (IRF7, IRF5, and IRF1). Many 
affected pathways involved innate im-
munity, including IFN signaling, NF-B 
signaling, DC maturation, antigen pre-
sentation, and inflammasome signaling.
The authors then compared the gene   
expression profiles induced by poly ICLC 
with those induced by the live YFV-
17D vaccine. Pathway analysis revealed 
up-regulation of many similar transcrip-
tional and signal transduction pathways 
at day 1 after poly ICLC administra-
tion and day 7 after the live YFV-17D 
vaccine. Of note, poly ICLC induced JEM Vol. 208, No. 12 2349
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